Brief: Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat
30/05/2026 16:15
BRIEF-Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat May 30 (Reuters) - Mineralys Therapeutics Inc MLYS.O:
MINERALYS THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 3 LAUNCH-HTN TRIAL OF LORUNDROSTAT IN PARTICIPANTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE AT EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION (ESH 2026)
Source text: ID:nGNXbT03HL
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway